Timely Genetic Testing and Therapy Management in Patients With gBRCA-Mutated Metastatic Breast Cancer Receiving Talazoparib

Talazoparib is a poly(ADP-ribose) polymerase (PARP) inhibitor that has demonstrated strong efficacy with manageable side effects for patients with germline breast cancer susceptibility genes 1 or 2 (gBRCA1/2)- mutated, human epidermal growth factor receptor 2–negative, locally advanced or metastatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez, Ashley, Jones, Tiffany, Ryan, Joanne C., Barnett, Chad M., Soussou, Elpitha L., Donahue, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2022
Materias:
Grand Rounds
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514123/
https://www.ncbi.nlm.nih.gov/pubmed/36199494
http://dx.doi.org/10.6004/jadpro.2022.13.7.6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514123/
https://www.ncbi.nlm.nih.gov/pubmed/36199494
http://dx.doi.org/10.6004/jadpro.2022.13.7.6

Ejemplares similares